Compare Sanofi SA (SNY) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs ProShares UltraPro S&P500 — how do they compare? Sanofi SA trades at $42.95 (market cap $103.41B), while ProShares UltraPro S&P500 trades at $147.47. The key difference: Sanofi SA pays a 5.65% dividend while ProShares UltraPro S&P500 pays none, and ProShares UltraPro S&P500 is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| SNY | UPRO | |
|---|---|---|
Market Cap | $103.41B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $52.34 | $157.66 |
52-Week Low | $41.33 | $89.29 |
Enterprise Value | $123.44B | — |
Dividend Yield | 5.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
UPRO trades at $149.32, down 1.69% today, with a neutral technical signal overall. Moving averages suggest a bullish trend, but oscillators indicate neutral momentum. Support lies at $148, with resistance at $151. Recent news highlights S&P 500 volatility amid geopolitical tensions and AI-driven market concentration risks, influencing this leveraged ETF's performance.
The outlook for UPRO remains tied to S&P 500 movements, with potential upside from AI productivity gains but risks from high valuations and Fed policy. Investors face amplified volatility due to leverage, requiring caution amid economic uncertainties. Near-term direction hinges on market sentiment and macroeconomic indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
